Jaffetilchin Investment Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Jaffetilchin Investment Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,124	Closed	-$325K	–	369
2023 Q2	$325K	Sell	4,124 -552	-12%	-$43.2K	0.03%	269
2023 Q1	$363K	Buy	4,676 +979	+26%	+$75.5K	0.04%	253
2022 Q4	$287K	Buy	+3,697	New	+$273K	0.04%	282
2018 Q4	–	Sell	-7,619	Closed	-$490K	–	332
2018 Q3	$490K	Sell	7,619 -94	-1%	-$5.86K	0.1%	158
2018 Q2	$455K	Buy	+7,713	New	+$447K	0.1%	177

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Jaffetilchin Investment Partners's PPH Position: Q3 2023 in Review

Jaffetilchin Investment Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2023, closing a stake of 4,124 shares — an estimated $325K sold.

Jaffetilchin Investment Partners first reported a position in PPH in Q2 2018 and held it in 5 quarters. The position peaked at $490K in Q3 2018. 102 funds tracked by Wall St. Rank hold PPH as of Q3 2023.

Jaffetilchin Investment Partners reported no remaining VanEck Pharmaceutical ETF position as of Q3 2023 after selling out during the quarter.
Jaffetilchin Investment Partners sold 4,124 VanEck Pharmaceutical ETF shares in Q3 2023, an estimated $325K.
Jaffetilchin Investment Partners first reported a position in VanEck Pharmaceutical ETF in Q2 2018 and held it in 5 quarters.
Jaffetilchin Investment Partners's VanEck Pharmaceutical ETF position peaked at $490K in Q3 2018.
102 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2023.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2023, filed 13 Nov 2023.